Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gout drug allopurinol may boost heart function in african americans with resistant hypertension

NCT ID NCT05888233

Symptom relief Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This study tests whether allopurinol, a common gout medication, can improve heart function in African American veterans with resistant hypertension. Participants take allopurinol for 8 weeks, and researchers measure changes in heart function, exercise ability, and quality of life. The trial involves 40 people in Birmingham, Alabama.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Allopurinol
What this could lead to
If it works, this could point toward a new way to improve heart function and quality of life for African Americans with resistant hypertension.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. Allopurinol can cause side effects like rash or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

40 people

The number who actually took part.

Started

Sep 2024

Finished

Aug 2026

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Veteran 2. African American 3. Resistant hypertension diagnosis (defined as blood pressure greater than 140/90 millimeters of mercury (mmHg) at 2 clinic visits despite the use of 3 antihypertensive medications at pharmacologically effective doses) 4. Locale - Birmingham, AL and surrounding areas Exclusion Criteria: 1. History of heart failure 2. Chronic kidney disease (estimated creatinine clearance \< 60 milliliters per minute (ml/min) 3. Chronic steroid therapy 4. Known coronary artery disease 5. Known causes of secondary hypertension 6. Already taking Allopurinol Magnetic Resonance Imaging Exclusion 1. Claustrophobia 2. Cardiac implantable electronic device (permanent pacemaker and/or intracardiac defibrillator) 3. Metal clips and/devices or other item that specifically prohibit safe cardiovascular magnetic resonance imaging (CMR)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure preserved ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure hypertensive disorder resistant hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure preserved ejection fraction Resistant hypertension

Contacts and locations

Locations

  • Birmingham VA Medical Center, Birmingham, AL

    Birmingham, Alabama, 35233-1927, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.